These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 17084715)

  • 1. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
    Dhainaut JF;
    Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.
    Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP
    Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
    Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W
    Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
    Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
    Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
    Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
    Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
    Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
    Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
    Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.